[Source: Market Watch] – AmpliMed Corporation, a cancer therapeutics company, today announced results from AMP-019, a randomized double-blind, placebo-controlled Phase II screening trial designed to determine if a Phase III trial was warranted for the combination of gemcitabine (Gemzar, Eli Lilly) plus Amplimexon (AmpliMed Corporation) in patients with advanced pancreatic ductal adenocarcinoma of the pancreas. The statistical design required a 40 percent improvement in overall survival, the primary endpoint, for a positive outcome. Unfortunately, the results showed no improvement in overall survival for the combination of gemcitabine and Amplimexon.
AmpliMed reports results from AMP-019
July 9, 2010